Ocular toxicities could be the reason.
ApexOnco Front Page
Recent articles
The group cans ZW171 after “on-target, off-tumour toxicity”.
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
The group has canned its first-generation project, hoping that a follow-on will reach more patients.
LaNova, which licensed a PD-1 x VEGF to Merck, is acquired by another Chinese player.
The company will start a phase 2/3 trial of its Mirati-originated PRMT5 inhibitor in autumn.
The disappointing Pynnacle trial is set to yield registrational data.
